1431727-20-6

Basic information

• Product Name: N-(2-((3-aminophenyl)amino)pyrimidin-5-yl)-2-methyl-5-(3-(trifluoromethyl)benzamido)benzamide
• Synonyms: N-(2-((3-aminophenyl)amino)pyrimidin-5-yl)-2-methyl-5-(3-(trifluoromethyl)benzamido)benzamide
• CAS NO: 1431727-20-6
• Molecular Weight: 506.487
• Mol File: 1431727-20-6.mol

Chemical Properties

• CAS DataBase Reference: N-(2-((3-aminophenyl)amino)pyrimidin-5-yl)-2-methyl-5-(3-(trifluoromethyl)benzamido)benzamide(CAS DataBase Reference)
• NIST Chemistry Reference: N-(2-((3-aminophenyl)amino)pyrimidin-5-yl)-2-methyl-5-(3-(trifluoromethyl)benzamido)benzamide(1431727-20-6)
• EPA Substance Registry System: N-(2-((3-aminophenyl)amino)pyrimidin-5-yl)-2-methyl-5-(3-(trifluoromethyl)benzamido)benzamide(1431727-20-6)

Safety Data

• Hazardous Substances Data: 1431727-20-6(Hazardous Substances Data)

Upstream product

• 2840-04-2 5-amino-2-methylbenzoic acid 
• 108-45-2 m-phenylenediamine 
• 1431727-37-5 tert-butyl (3-((5-nitropyrimidin-2-yl)amino)phenyl)carbamate 
• 68621-88-5 (3-aminophenyl)carbamic acid tert-butyl ester 
• 896160-43-3 2-methyl-5-(3-(trifluoromethyl)benzamido)benzoic acid 
• 1431727-38-6 tert-butyl 3-(5-aminopyrimidin-2-ylamino)phenylcarbamate 
• 2251-65-2 3-(Trifluoromethyl)benzoyl chloride 
• 454-92-2 3-(trifluoromethyl)benzoic acid 

Downstream Products

• 1613228-43-5 2-methyl-N-(2-(3-propionamidophenylamino)pyrimidin-5-yl)-5-(3-(trifluoromethyl)benzamido)benzamide 
• 1613228-45-7 2-methyl-N-(2-(3-(N-propionylpropionamido)phenylamino)-pyrimidin-5-yl)-5-(3-(trifluoromethyl)benzamido)benzamide 
• 1431727-00-2 N-(2-(3-acrylamidophenylamino)pyrimidin-5-yl)-2-methyl-5-(3-(trifluoromethyl)benzamido)benzamide 
• 1431727-06-8 N-(2-(3-(N-acryloylacrylamido)phenylamino)pyrimidin-5-yl)-2-methyl-5-(3-(trifluoromethyl)benzamido)benzamide 
• 1613228-47-9 (E)-N-(2-(3-but-2-enamidophenylamino)pyrimidin-5-yl)-2-methyl-5-(3-(trifluoromethyl)benzamido)benzamide 
• 1613228-48-0 (E)-N-(2-(3-(4-(dimethylamino)but-2-enamido)phenylamino)-pyrimidin-5-yl)-2-methyl-5-(3-(trifluoromethyl)benzamido)-benzamide 
• 1431727-02-4 2-methyl-5-(3-(trifluoromethyl)benzamido)-N-(2-(3-(vinylsulfonamido)phenylmino)pyrimidin-5-yl)benzamide 
• 1613228-49-1 N-(2-(3-(2-chloroacetamido)phenylamino)pyrimidin-5-yl)-2-methyl-5-(3-(trifluoromethyl)benzamido)benzamide 
• 1613228-50-4 2-methyl-N-(2-(3-(2-(3-oxobenzo[d]isothiazol-2(3H)-yl)-acetamido)phenylamino)pyrimidin-5-yl)-5-(3-(trifluoromethyl)-benzamido)benzamide 
• 1431727-04-6 N-(2-(3-(2-acrylamidoacetamido)phenylamino)pyrimidin-5-yl)-2-methyl-5-(3-(trifluoromethyl)benzamido)benzamide 

Relevant articles and documents

Bruton's tyrosine kinase inhibitor

The invention discloses a compound with a general formula (I), wherein the compound is capable of inhibiting Btk, and the groups are disclosed in the invention. The compound can be used for treating autoimmune diseases, heterologous immunization diseases, cancers, or thromboembolism diseases. The invention also discloses a pharmaceutical composition containing the compound represented by formula (I). The Bruton's tyrosine kinase inhibitor is capable of inhibiting the activity of Bruton's tyrosine kinas through covalent binding such as a covalent reversible mode.

KINASE INHIBITOR AND METHOD FOR TREATMENT OF RELATED DISEASES

Disclosed is a compound of (aminophenylamino) pyrimidyl benzamides and a synthesis method thereof. The compound has Btk-inhibition activity and can be used to treat autoimmune diseases, heteroimmune diseases, cancers or thromboembolic diseases.

KINASE INHIBITOR AND METHOD FOR TREATMENT OF RELATED DISEASES

Disclosed is a compound of (aminophenylamino) pyrimidyl benzamides and a synthesis method thereof. The compound has Btk-inhibition activity and can be used to treat autoimmune diseases, heteroimmune diseases, cancers or thromboembolic diseases.

Discovery of a series of 2,5-diaminopyrimidine covalent irreversible inhibitors of Bruton's tyrosine kinase with in vivo antitumor activity

Bruton's tyrosine kinase (Btk) is an attractive drug target for treating several B-cell lineage cancers. Ibrutinib is a first-in-class covalent irreversible Btk inhibitor and has demonstrated impressive effects in multiple clinical trials. Herein, we present a series of novel 2,5-diaminopyrimidine covalent irreversible inhibitors of Btk. Compared with ibrutinib, these inhibitors exhibited a different selectivity profile for the analyzed kinases as well as a dual-action mode of inhibition of both Btk activation and catalytic activity, which counteracts a negative regulation loop for Btk. Two compounds from this series, 31 and 38, showed potent antiproliferative activities toward multiple B-cell lymphoma cell lines, including germinal center B-cell-like diffuse large B cell lymphoma (GCB-DLBCL) cells. In addition, compound 31 significantly prevented tumor growth in a mouse xenograft model.